Clinical Research Directory
Browse clinical research sites, groups, and studies.
Reduction of Anticholinergic Medications Among Persons With Schizophrenia or Other Psychiatric Disorders
Sponsor: University of Pittsburgh
Summary
The goal of this study is to reduce Anticholinergic Medication (ACM) in persons with psychoses or serious mental illness, when these medications are no longer needed.
Official title: Reduction of Anticholinergic Medications Project (RAMP) Among Persons With Schizophrenia or Other Psychiatric Disorders Across UPMC Behavioral Healthcare Partner Organizations Using a Stepped-wedge, Randomized Trial Study Design.
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
111
Start Date
2025-07-16
Completion Date
2026-05
Last Updated
2025-08-06
Healthy Volunteers
No
Interventions
Reduction of anticholinergic medication
Shared decision making between the patient and prescriber will determine the timing and speed of reduction over a period of 12 to 16 weeks. Some patients will be discontinued from these anticholinergic medications (benztropine/trihexyphenidyl), others will be tapered from their original dosage but not completely discontinued, and some patients may not be able to taper the anticholinergic medications at all.
Locations (4)
Western Behavioral Health of the Alleghenies
Altoona, Pennsylvania, United States
UPMC Western Behavioral Health at Safe Harbor
Erie, Pennsylvania, United States
Western Behavioral Health Mon Yough
McKeesport, Pennsylvania, United States
Comprehensive Recovery Services (Pittsburgh) of Western Psychiatric Hospital, Ambulatory Clinics and Residential Programs - UPMC, Pittsburgh, PA
Pittsburgh, Pennsylvania, United States